Skip to main content
. Author manuscript; available in PMC: 2017 Apr 5.
Published in final edited form as: J Biotechnol. 2016 Jan 18;221:1–12. doi: 10.1016/j.jbiotec.2016.01.015

Fig. 5.

Fig. 5

Treatment of a GCase-Knockout (GCKO) immortalized mouse neuronal cell line with Tat-GCase or RDP-IgAh-GCase dramatically reduced glucosylsphingosine (GlcSph) accumulation. Duplicate sets of three wells were treated with 10 μg/mL purified protein or fresh medium only for 72 h with complete medium changes every 24 h. For each triplicate treatment condition, wells were pooled for analysis. Accumulated GlcSph was quantified using LC–MS/MS analysis and data was normalized to the total protein detected in the cell lysate. Duplicate GlcSph data points, displayed in the table, were averaged for graphical display. Error bars represent one standard deviation from the mean. The GCKO cell line was not found to accumulate glucosylceramide.